- £169.69bn
- £188.02bn
- $45.81bn
- 73
- 15
- 48
- 39
REG - Official List - Official List Notice
AnnouncementREG - Stock Exch Notice - Admission to Trading - 01/09/2022
AnnouncementREG - AstraZeneca PLC - Evusheld approved for COVID-19 in Japan
AnnouncementREG - AstraZeneca PLC - Farxiga reduced risk of CV death or worsening HF
AnnouncementREG - AstraZeneca PLC - Farxiga shows CV mortality benefit across EF range
AnnouncementREG - AstraZeneca PLC - Tagrisso approved in Japan for early lung cancer
AnnouncementREG - AstraZeneca PLC - Ultomiris approved in Japan for gMG
AnnouncementREG - AstraZeneca PLC - Lynparza approved in Japan for early breast cancer
AnnouncementREG - AstraZeneca PLC - Lynparza granted FDA priority review for PROpel
AnnouncementREG - AstraZeneca PLC - Enhertu improved PFS in mBC in DESTINY-Breast02
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Enhertu approved in US for HER2-mutant NSCLC
AnnouncementREG - AstraZeneca PLC - Acquisition of TeneoTwo completed
AnnouncementREG - AstraZeneca PLC - Enhertu approved in the US for HER2-low mBC
AnnouncementREG - AstraZeneca PLC - Lynparza approved in EU for early breast cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Chair succession
Announcement